Strategic Partners Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Strategic Partners yıllık ortalama 42.7% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 7.7% annual. Gelirler azalıyor .

Anahtar bilgiler

42.7%

Kazanç büyüme oranı

49.5%

EPS büyüme oranı

Biotechs Sektör Büyümesi	-14.6%
Gelir büyüme oranı	-5.1%
Özkaynak getirisi	-71.0%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Strategic Partners nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:1TB0 Gelir, gider ve kazançlar (DKK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	0	-11	2	0
31 Mar 24	0	-19	7	0
31 Dec 23	0	-26	13	0
30 Jun 23	0	-27	27	0
31 Mar 23	0	-32	34	0
31 Dec 22	0	-38	41	0
30 Jun 22	0	-48	53	0
31 Mar 22	0	-63	68	0
31 Dec 21	0	-78	83	0
30 Sep 21	12	-327	204	131
30 Jun 21	0	-437	226	194
31 Mar 21	0	-535	237	278
31 Dec 20	0	-633	247	361
30 Sep 20	0	-529	177	336
30 Jun 20	0	-425	106	311
31 Mar 20	0	-381	78	298
31 Dec 19	0	-337	51	285
30 Sep 19	0	-312	46	266
30 Jun 19	0	-286	46	242
31 Mar 19	0	-258	41	218
31 Dec 18	0	-230	35	197
30 Sep 18	0	-206	39	170
30 Jun 18	0	-182	41	145
31 Mar 18	0	-154	37	121
31 Dec 17	0	-126	33	98
30 Sep 17	0	-104	23	86
30 Jun 17	0	-82	13	75
31 Mar 17	0	-70	10	65
31 Dec 16	0	-58	8	56
31 Dec 15	0	-53	8	51

Kaliteli Kazançlar: 1TB0 şu anda kârlı değil.

Büyüyen Kar Marjı: 1TB0 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 1TB0 kârlı değildir, ancak son 5 yılda zararlarını yılda 42.7% oranında azaltmıştır.

Büyüme Hızlandırma: 1TB0 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 1TB0 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -20.8% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 1TB0 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -70.96% ) sahiptir.

Strategic Partners Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Orphazyme A/S to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Orphazyme A/S to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Orphazyme A/S to Report First Half, 2021 Results on Aug 24, 2021

Recent updates

New major risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Financial data availability

No independent directors

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO

Orphazyme A/S Announces Board Changes

Orphazyme A/S to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Orphazyme A/S Revises Earnings Guidance for the Year 2022

Orphazyme American Depositary Shares - Sponsored to Be Deleted from Other OTC

Orphazyme A/S Announces Board Appointment

Orphazyme A/S Provides Earnings Guidance for the Full Year of 2022

KemPharm Denmark A/S acquired Substantially All Assets and Business Activities of Orphazyme A/S for $18 million.

Orphazyme A/S Announces Executive Changes

Orphazyme A/S(CPSE:ORPHA) dropped from S&P Global BMI Index

Orphazyme A/S announced delayed amended 20-F filing

Orphazyme A/S announced delayed 20-F filing

Orphazyme A/S to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Orphazyme A/S, Annual General Meeting, May 21, 2022

Forecast to breakeven in 2024

Orphazyme A/S Announces Update on Regulatory Review of Arimoclomol in the European Union

Orphazyme A/S Elects Andrew Mercieca as Member of the Board of Directors

Orphazyme Provides Update for Planned NDA Resubmission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the United States

Orphazyme to Present Additional Data on Arimoclomol’s Mechanism of Action During 2022 Annual Worldsymposium™

Orphazyme A/S Announces CEO Changes

Orphazyme A/S Revises Earnings Guidance for the Year 2021

Forecast to breakeven in 2024

Orphazyme A/S Maintains its Outlook for the Full Year 2021

Orphazyme A/S Announces Publication of Results from Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C in the Journal of Inherited Metabolic Disease

Independent Director Martijn Kleijwegt has left the company

Independent Director Remi P. Droller has left the company

Independent Director Anders Hedegaard has left the company

CytRx Corporation Announces 24-Month Interim Results of an Open-Label Extension Trial of Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Orphazyme Provides Earnings Guidance for the Year of 2021

Orphazyme A/S Announces Topline Data from Pivotal Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

Independent Director has left the company

Orphazyme A/S Appoints Christophe Bourdon as Chief Executive Officer, Effective on April 1, 2021

Orphazyme A/S to Showcase Data on Arimoclomol in Niemann-Pick Disease Type C During the 2021 Annual Worldsymposium™

New 90-day high: €10.56

CytRx Corporation Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C

Orphazyme A/S Announces the U.S. Food and Drug Administration Has Extended the Review Period of the New Drug Application

New 90-day low: €7.41

Orphazyme A/S Announces Executive Changes

Orphazyme A/S, Annual General Meeting, Mar 25, 2021

Orphazyme A/S to Report First Half, 2021 Results on Aug 24, 2021

Orphazyme A/S Submits European Marketing Authorisation Application for Arimoclomol for Treatment of Niemann-Pick Disease Type C

CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol

New 90-day low: €8.67

Orphazyme A/S has completed a Follow-on Equity Offering in the amount of $83.777606 million.

Orphazyme A/S Provides Update on Previously Announced Global Offering

New 90-day low: €9.92

Orphazyme A/S Elects Carrolee Barlow as Board of Director

New 90-day low - €11.52

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin